Dr. Ian Johnson is an Adjunct Senior Research Fellow at UniSA Clinical & Health Sciences and the Senior Coordinator for Life Sciences at Telespazio, working with the European Space Agency.
With a robust research background in vesicular trafficking mechanisms of prostate cancer, monoclonal antibody development, and the effects of microgravity on cellular physiology and disease pathogenesis, Dr. Johnson is dedicated to advancing the diagnosis, prognosis, and treatment of diseases by identifying new biomarkers of altered cellular processes.
Dr. Johnson has authored over 30 peer-reviewed articles, holds patents for cancer detection methods, and serves as a reviewer and guest editor for various scientific journals.
Please note that... Read more
About me
Dr. Ian Johnson is an Adjunct Senior Research Fellow at UniSA Clinical & Health Sciences and the Senior Coordinator for Life Sciences at Telespazio, working with the European Space Agency.
With a robust research background in vesicular trafficking mechanisms of prostate cancer, monoclonal antibody development, and the effects of microgravity on cellular physiology and disease pathogenesis, Dr. Johnson is dedicated to advancing the diagnosis, prognosis, and treatment of diseases by identifying new biomarkers of altered cellular processes.
Dr. Johnson has authored over 30 peer-reviewed articles, holds patents for cancer detection methods, and serves as a reviewer and guest editor for various scientific journals.
Please note that Dr. Johnson is not accepting new PhD candidates at UniSA.
About me
Doctor of Philosophy University of South Australia
Bachelor of Science(Honours) University of Birmingham
Research
Excludes commercial-in-confidence projects.
Diagnostic and prognostic biomarker test for prostate cancer, EnVision Sciences Pty Ltd, 01/01/2017 - 30/10/2018
Altered endosome trafficking in prostate cancer, PCFA Research Program, 01/01/2017 - 31/12/2017
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2024 |
Open access
|
2023 |
Open access
2
|
2023 |
Open access
4
|
2022 |
Open access
9
7
1
|
2020 |
Open access
8
8
|
Year | Output |
---|---|
2024 |
Open access
|
2024 |
Open access
|
2024 |
Open access
2
|
2023 |
Open access
2
|
2023 |
8
|
2023 |
Open access
2
|
2023 |
Open access
3
1
|
2023 |
Open access
4
|
2023 |
Open access
8
122
|
2023 |
Open access
14
13
83
|
2023 |
Open access
1
2
|
2023 |
Open access
5
|
2022 |
Open access
42
34
1
|
2022 |
Open access
9
7
1
|
2022 |
Open access
5
8
42
|
2020 |
Open access
8
8
|
2019 |
|
2019 |
Open access
5
5
1
|
2018 |
Open access
31
31
3
|
2018 |
Open access
22
1
|
2018 |
Open access
34
5
|
2018 |
Open access
31
27
9
|
2016 |
27
25
4
|
2015 |
Open access
41
41
2
|
2015 |
Open access
35
32
11
|
2014 |
19
17
1
|
2014 |
Open access
37
36
11
|
Research
Details | Registry | Status |
---|---|---|
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
AU | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
EP | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
SG | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
US | Filed |
Methods for detecting prostate cancer Brooks, Doug; Parkinson-Lawrence, Emma; Johnson, Ian; Butler, Lisa; Weigert, Roberto |
WO | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Aarhus University | DENMARK |
Austin Health | AUSTRALIA |
Children's Hospital Los Angeles | UNITED STATES |
Curtin University | AUSTRALIA |
Deakin University | AUSTRALIA |
Flinders Medical Centre | AUSTRALIA |
Flinders University | AUSTRALIA |
German Aerospace Center | GERMANY |
La Trobe University | AUSTRALIA |
Lucerne University of Applied Sciences and Arts | SWITZERLAND |
Malaghan Institute of Medical Research | NEW ZEALAND |
Monash University | AUSTRALIA |
National Institute of Child Health and Human Development | UNITED STATES |
National Institutes of Health | MALAYSIA |
National Research Council of Italy | ITALY |
NIDCR | UNITED STATES |
Otto von Guericke University Magdeburg | GERMANY |
Queensland University of Technology | AUSTRALIA |
RMIT University | AUSTRALIA |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
The Coombe Hospital | IRELAND |
Trinity College Dublin | IRELAND |
University College Dublin | IRELAND |
University Hospital Magdeburg | GERMANY |
University of Adelaide | AUSTRALIA |
University of Bologna | ITALY |
University of British Columbia | CANADA |
University of Cambridge | UNITED KINGDOM |
University of Dublin | IRELAND |
University of Melbourne | AUSTRALIA |
University of Queensland | AUSTRALIA |
University of South Australia | AUSTRALIA |
University of Sydney | AUSTRALIA |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
AwardThe Freemasons Foundation |
2014 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
111081 - Introducing a new paradigm for specific targeting of ovarian cancer cells with engineered nanoparticles, using G protein-coupled receptors as molecular entry points | Current |
Defining critical changes in lipid metabolism during prostate cancer progression | Current |
The role of membrane trafficking in prostate cancer metastasis | Current |
The roles of molecular machinery in androgen receptor trafficking and development of prostate cancer | Current |
Development of monoclonal antibody targeted therapeutics for prostate cancer | Completed |